Abstract
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic attempts have been tried involving intra aortic balloon pump and inotropic agents infusion (such as beta-adrenergic agonists and phosphodiesterase inhibitors)
Levosimendan is new inotropic agent; it is a calcium-sensitising inotropic agent and a vasodilator used in the treatment of heart failure. In the last ten years several reports have been published on levosimendan. The inotropic efficacy of levosimendan is dose-dependent and equal or even superior to any of the other commercially available inotropic agents.
The aim of the present review is to describe experimental and clinical effects of perioperative treatment with levosimendan.
Keywords: Levosimendan, heart failure, cardiac surgery.
Current Pharmaceutical Design
Title:Levosimendan Preoperative
Volume: 19 Issue: 22
Author(s): Andrea Rognoni, Alessandro Lupi, Chiara Cavallino, Alessia Veia, Sara Bacchini, Roberta Rosso, Gioel Gabrio Secco and Angelo Sante Bongo
Affiliation:
Keywords: Levosimendan, heart failure, cardiac surgery.
Abstract: During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic attempts have been tried involving intra aortic balloon pump and inotropic agents infusion (such as beta-adrenergic agonists and phosphodiesterase inhibitors)
Levosimendan is new inotropic agent; it is a calcium-sensitising inotropic agent and a vasodilator used in the treatment of heart failure. In the last ten years several reports have been published on levosimendan. The inotropic efficacy of levosimendan is dose-dependent and equal or even superior to any of the other commercially available inotropic agents.
The aim of the present review is to describe experimental and clinical effects of perioperative treatment with levosimendan.
Export Options
About this article
Cite this article as:
Rognoni Andrea, Lupi Alessandro, Cavallino Chiara, Veia Alessia, Bacchini Sara, Rosso Roberta, Secco Gioel Gabrio and Sante Bongo Angelo, Levosimendan Preoperative, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220005
DOI https://dx.doi.org/10.2174/1381612811319220005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Regulation of Blood Flow by Prostaglandins
Current Vascular Pharmacology Utility of γH2AX as a Molecular Marker of DNA Double-Strand Breaks in Nuclear Medicine: Applications to Radionuclide Therapy Employing Auger Electron-Emitting Isotopes
Current Radiopharmaceuticals New Recombinant Serotypes of AAV Vectors
Current Gene Therapy Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation
Current Cardiology Reviews Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry Regulation of the Endoplasmic Reticulum Ca2+-Store in Cancer
Anti-Cancer Agents in Medicinal Chemistry Lipids and Lysosomes
Current Drug Metabolism Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Coronaviruses Drug-Induced Pulmonary Hypertension in Newborns: A Review.
Current Vascular Pharmacology 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry